Xinqing Fan1, Ned Snyder. 1. Department of Gastroenterology, University of Texas Medical Branch, 301 University Blvd., Route 0764, Galveston, TX 77555, USA. xingfan@utmb.edu
Abstract
BACKGROUND: Gastroesophageal reflux disease is associated with a significantly increased risk of Barrett's esophagus (BE) and adenocarcinoma of the esophagus. Racial differences in the prevalence of BE are controversial. Our purpose was to study the prevalence of Barrett's esophagus in patients with and without gastroesophageal reflux disease (GERD) symptoms, and the differences between these two groups in terms of race, age, and sex. METHODS: Esophagogastroduodenoscopy (EGD) reports from the PENTAX EndoPRO database for the Endoscopy Unit at the University of Texas Medical Branch from 2005 to 2007 were reviewed. Four hundred and ten patients who underwent upper endoscopy because of GERD symptoms that were not responding to proton pump inhibitor (PPI) therapy or with alarm symptoms and 4,047 patients undergoing upper endoscopy for other reasons without GERD symptoms were identified. RESULTS: BE was significantly more common among males. The prevalence of BE was higher in patients with GERD symptoms than those without GERD symptoms. Overall, more cases of BE, dysplasia, and adenocarcinoma were found among the patients without GERD symptoms than those that underwent endoscopy because of GERD symptoms. The prevalence of BE among Caucasian, African American, Hispanic, and "other" groups with GERD symptoms were 5%, 2.56%, 4.4%, and 0%, respectively. The prevalence of BE among these racial groups without GERD symptoms were 1.9%, 0.9%, 1.57%, and 0.8%, respectively. The association between race and BE was not statistically significant (df = 3, P = 0.2628), including after adjusting for the presence of GERD symptoms (df = 3, P = 0.2947). Patients without GERD symptoms that presented with BE were significantly older than the patients without BE (P < 0.01). CONCLUSIONS: BE is a male-dominant disease. The prevalence of Barrett's esophagus was not significant different among Caucasian, Hispanics, and African Americans. Most of the patients with BE, dysplasia, and adenocarcinoma did not have GERD symptoms.
BACKGROUND:Gastroesophageal reflux disease is associated with a significantly increased risk of Barrett's esophagus (BE) and adenocarcinoma of the esophagus. Racial differences in the prevalence of BE are controversial. Our purpose was to study the prevalence of Barrett's esophagus in patients with and without gastroesophageal reflux disease (GERD) symptoms, and the differences between these two groups in terms of race, age, and sex. METHODS: Esophagogastroduodenoscopy (EGD) reports from the PENTAX EndoPRO database for the Endoscopy Unit at the University of Texas Medical Branch from 2005 to 2007 were reviewed. Four hundred and ten patients who underwent upper endoscopy because of GERD symptoms that were not responding to proton pump inhibitor (PPI) therapy or with alarm symptoms and 4,047 patients undergoing upper endoscopy for other reasons without GERD symptoms were identified. RESULTS: BE was significantly more common among males. The prevalence of BE was higher in patients with GERD symptoms than those without GERD symptoms. Overall, more cases of BE, dysplasia, and adenocarcinoma were found among the patients without GERD symptoms than those that underwent endoscopy because of GERD symptoms. The prevalence of BE among Caucasian, African American, Hispanic, and "other" groups with GERD symptoms were 5%, 2.56%, 4.4%, and 0%, respectively. The prevalence of BE among these racial groups without GERD symptoms were 1.9%, 0.9%, 1.57%, and 0.8%, respectively. The association between race and BE was not statistically significant (df = 3, P = 0.2628), including after adjusting for the presence of GERD symptoms (df = 3, P = 0.2947). Patients without GERD symptoms that presented with BE were significantly older than the patients without BE (P < 0.01). CONCLUSIONS: BE is a male-dominant disease. The prevalence of Barrett's esophagus was not significant different among Caucasian, Hispanics, and African Americans. Most of the patients with BE, dysplasia, and adenocarcinoma did not have GERD symptoms.
Authors: Gary J Kelloff; Scott M Lippman; Andrew J Dannenberg; Caroline C Sigman; Homer L Pearce; Brian J Reid; Eva Szabo; V Craig Jordan; Margaret R Spitz; Gordon B Mills; Vali A Papadimitrakopoulou; Reuben Lotan; Bharat B Aggarwal; Robert S Bresalier; Jeri Kim; Banu Arun; Karen H Lu; Melanie E Thomas; Helen E Rhodes; Molly A Brewer; Michele Follen; Dong M Shin; Howard L Parnes; Jill M Siegfried; Alison A Evans; William J Blot; Wong-Ho Chow; Patricia L Blount; Carlo C Maley; Kenneth K Wang; Stephen Lam; J Jack Lee; Steven M Dubinett; Paul F Engstrom; Frank L Meyskens; Joyce O'Shaughnessy; Ernest T Hawk; Bernard Levin; William G Nelson; Waun Ki Hong Journal: Clin Cancer Res Date: 2006-06-15 Impact factor: 12.531
Authors: Douglas K Rex; Oscar W Cummings; Michael Shaw; Mark D Cumings; Roy K H Wong; Raj S Vasudeva; Donal Dunne; Emad Y Rahmani; Debra J Helper Journal: Gastroenterology Date: 2003-12 Impact factor: 22.682
Authors: William D Hazelton; Kit Curtius; John M Inadomi; Thomas L Vaughan; Rafael Meza; Joel H Rubenstein; Chin Hur; E Georg Luebeck Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-04-30 Impact factor: 4.254
Authors: Joe E Khoury; Sian Chisholm; M Mazen Jamal; Carlos Palacio; Sunitha Pudhota; Kenneth J Vega Journal: Dig Dis Sci Date: 2011-09-11 Impact factor: 3.199
Authors: Sarina Pasricha; Nan Li; William J Bulsiewicz; Richard I Rothstein; Anthony Infantolino; Atilla Ertan; Daniel S Camara; Evan S Dellon; George Triadafilopoulos; Charles J Lightdale; Ryan D Madanick; William D Lyday; Raman V Muthusamy; Bergein F Overholt; Nicholas J Shaheen Journal: Gastrointest Endosc Date: 2015-04-01 Impact factor: 9.427
Authors: Katie S Nason; Promporn Paula Wichienkuer; Omar Awais; Matthew J Schuchert; James D Luketich; Robert W O'Rourke; John G Hunter; Cynthia D Morris; Blair A Jobe Journal: Arch Surg Date: 2011-07